Rafael Holdings submitted an NDA for remibetadex in October 2026 after a Phase 3 study showed a 71% slowing of disease progression in a prespecified subgroup, despite missing the primary endpoint.
The 8-K investor presentation restates that the Phase 3 TransportNPC study did not meet its primary endpoint, but a prespecified analysis showed a 71% relative slowing of disease progression (p=0.046), the NDA was submitted in October 2026, and PRV eligibility could bring non-dilutive value (recent vouchers sold for ~$200M on average). These offsetting positives and negatives leave no clear near-term direction for RFL.
Rafael Holdings, Inc. has submitted an NDA for its lead candidate, remibetadex, following the completion of its Phase 3 TransportNPC study in September 2026. While the study failed to meet its primary endpoint in the overall population, a prespecified analysis of patients on miglustat and/or leucine showed a 71% relative slowing of disease progression. The company faces significant financial risks, including concerns regarding its ability to continue as a going concern.
No. The primary endpoint of the 96-week TransportNPC study in Niemann-Pick disease type C was not statistically significant, although a prespecified analysis showed a 71% relative slowing of disease progression (p=0.046) in patients on remibetadex plus miglustat/leucine versus placebo plus miglustat/leucine.
The company says the Rare Pediatric Disease PRV program has been extended to September 2029 and that the four most recent publicly announced vouchers sold for an average of about $200M (ranging from $190M to $210M).